Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Neoleukin Therapeutics Inc (NLTX) USD0.000001

Sell:$2.90 Buy:$4.01 Change: $0.13 (3.67%)
NASDAQ:0.11%
Market closed |  Prices as at close on 18 September 2019 | Switch to live prices |
Sell:$2.90
Buy:$4.01
Change: $0.13 (3.67%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 18 September 2019 | Switch to live prices |
Sell:$2.90
Buy:$4.01
Change: $0.13 (3.67%)
Market closed |  Prices as at close on 18 September 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Contact details

Address:
401 Terry Ave N
SEATTLE
98109-5263
United States
Telephone:
+1 (206) 7322133
Website:
https://www.neoleukin.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NLTX
ISIN:
US64049K1043
Market cap:
$135.66 million
Shares in issue:
38.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jonathan Drachman
    Interim Chairman of the Board, Chief Executive Officer
  • Kamran Alam
    Chief Financial Officer, Vice President - Finance
  • Lloyd Mackenzie
    Chief Operating Officer, Vice President - R&D Operations
  • David Mitchell
    Vice President - Global Regulatory Affairs & Quality Assurance
  • Barbara Troupin
    Chief Medical Officer, Vice President - Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.